Zogenix International Limited

Zogenix, Inc.

Aradigm Corporation

Brooks M Boyd

Stephen J Farr

Jeffrey A Schuster

Sujata Mudumba

Glenn Arthur Morrison

Khawla Abu-Izza

David Hickman

Gul P Balwani

Stephan J Farr

John Whatley

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HTagonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Formulation for inhibiting formation of 5-HTagonists and methods of using same

Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

Metabolism resistant fenfluramine analogs and methods of using the same

A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.

Ketogenic diet compatible fenfluramine formulation

Formulation for inhibiting formation of 5-HT2B agonists and methods of using same

A needle free injector system and a method for delivering a formulation using this system are disclosed. The method comprises actuating a needle free injector to pressurize a liquid formulation and force the formulation through an orifice in a skin puncture phase followed by injection of the formulation during a delivery phase. The skin puncture phase is defined by a pressure profile vs. time curve after actuation which has a main pressure peak with a maximum pressure. The delivery phase occurs at a lower pressure than the maximum pressure of the main peak pressure. The device may have one or more orifices and pressurizing the formulation during the puncture phase and delivery phase to extrude the formulation through each orifice is structured so as to improve characteristics of needle free delivery.

Needle-free injectors and design parameters thereof that optimize injection performance

Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20&#xb0; C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second &#xb1;0.02 seconds.

Viscous formulations and their use in needle-free injection

Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20&#xb0; C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second&#xb1;0.02 seconds.

Growing community of inventors

Berkeley, CA, United States of America

Brooks M Boyd